Maravai LifeSciences Holdings Inc [NASDAQ: MRVI] slipped around -2.18 points on Wednesday, while shares priced at $4.70 at the close of the session, down -31.69%. The company report on November 7, 2023 at 4:05 PM that Maravai LifeSciences Reports Third Quarter 2023 Financial Results.
Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation.
Maravai LifeSciences Holdings Inc stock is now -67.16% down from its year-to-date (YTD) trading value. MRVI Stock saw the intraday high of $6.22 and lowest of $4.60 per share. The company’s 52-week high price is 16.90, which means current price is +2.17% above from all time high which was touched on 02/23/23.
Compared to the average trading volume of 2.43M shares, MRVI reached a trading volume of 12079496 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Maravai LifeSciences Holdings Inc [MRVI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MRVI shares is $9.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MRVI stock is a recommendation set at 1.82. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KeyBanc Capital Markets have made an estimate for Maravai LifeSciences Holdings Inc shares, keeping their opinion on the stock as Sector Weight, with their previous recommendation back on August 08, 2023.
The Average True Range (ATR) for Maravai LifeSciences Holdings Inc is set at 0.54, with the Price to Sales ratio for MRVI stock in the period of the last 12 months amounting to 1.14. The Price to Book ratio for the last quarter was 1.19, with the Price to Cash per share for the same quarter was set at 4.40. Price to Free Cash Flow for MRVI in the course of the last twelve months was 2.31 with Quick ratio for the last quarter at 8.70.
How has MRVI stock performed recently?
Maravai LifeSciences Holdings Inc [MRVI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.96. With this latest performance, MRVI shares dropped by -45.41% in over the last four-week period, additionally sinking by -61.22% over the last 6 months – not to mention a drop of -66.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRVI stock in for the last two-week period is set at 19.49, with the RSI for the last a single of trading hit 16.18, and the three-weeks RSI is set at 22.44 for Maravai LifeSciences Holdings Inc [MRVI]. The present Moving Average for the last 50 days of trading for this stock 8.68, while it was recorded at 6.41 for the last single week of trading, and 12.12 for the last 200 days.
Maravai LifeSciences Holdings Inc [MRVI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Maravai LifeSciences Holdings Inc [MRVI] shares currently have an operating margin of +66.33 and a Gross Margin at +80.55. Maravai LifeSciences Holdings Inc’s Net Margin is presently recorded at +24.94.
Return on Total Capital for MRVI is now 46.51, given the latest momentum, and Return on Invested Capital for the company is 23.09. Return on Equity for this stock inclined to 51.17, with Return on Assets sitting at 10.48. When it comes to the capital structure of this company, Maravai LifeSciences Holdings Inc [MRVI] has a Total Debt to Total Equity ratio set at 97.89. Additionally, MRVI Total Debt to Total Capital is recorded at 49.47, with Total Debt to Total Assets ending up at 23.38. Long-Term Debt to Equity for the company is recorded at 95.74, with the Long-Term Debt to Total Capital now at 48.38.
Reflecting on the efficiency of the workforce at the company, Maravai LifeSciences Holdings Inc [MRVI] managed to generate an average of $360,992 per employee. Receivables Turnover for the company is 6.68 with a Total Asset Turnover recorded at a value of 0.42.Maravai LifeSciences Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.70 and a Current Ratio set at 9.33.
Insider trade positions for Maravai LifeSciences Holdings Inc [MRVI]
The top three institutional holders of MRVI stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in MRVI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in MRVI stock with ownership which is approximately 5.7994%.
